Mesto antagonistov mineralokortikoidnykh retseptorov v terapii bol'nykh s KhSN


Cite item

Full Text

Abstract

Результаты проведенных клинических исследований убедительно показали, что применение антагонистов минералокортикоидных рецепторов (МР) дополнительно к стандартной терапии (ингибиторы ангиотензинпревращающего фермента – ИАПФ, b-адреноблокаторы, диуретики, дигоксин) увеличивает выживаемость, уменьшает число госпитализаций и улучшает клиническое состояние больных с легкой, умеренной и тяжелой хронической сердечной недостаточностью (ХСН; II–IV функционального класса – ФК) и сниженной фракцией выброса левого желудочка – ФВ ЛЖ (≤35%).

About the authors

Yu. F Osmolovskaya

ФГБУ РКНПК Минздрава РФ, Москва

Отдел заболеваний миокарда и сердечной недостаточности

S. N Tereshchenko

ФГБУ РКНПК Минздрава РФ, Москва

Отдел заболеваний миокарда и сердечной недостаточности

I. V Zhirov

ФГБУ РКНПК Минздрава РФ, Москва

Отдел заболеваний миокарда и сердечной недостаточности

References

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.
  2. Mc Machon E. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001; 1: 190–6.
  3. Weber K.T, Villarreal D. Aldosterone, and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993; 71 (Suppl. A): 3A–11A.
  4. Yasky J, Ledesma G.A, Tutera A, Collia L.F. A fixed - dose combination of furosemide and spironolactone in digitalized congestive heart failure patients. Pharmatherapeutica 1986; 4 (8): 480–5.
  5. Smith A.G. Spironolactone in the long - term management of patients with congestive heart failure. Curr Med Res Opin 1980; 7 (2): 131–6.
  6. Muller J. Spironolactone in the management of congestive heart failure: a rewiew. Clin Ther 1986; 9 (1): 63–76.
  7. Arriza J.L, Weinberger C, Cerelli G et al. Cloning of human mineralocorticoid receptor complementory DNA: structural and functional kinship with the glucocorticoid receptor. Sci 1987; 237 (4812): 268–75.
  8. Корочкин И.М., Матвеева И.В. Гормональные нарушения и лечение больных с рефрактерными формами застойной сердечной недостаточности. Кардиология. 1977; 17 (8): 36–43.
  9. Pierpont G.L, Francis G.S, Cohn J.N. Effect of captopril on renal function in patients with congestive heart failure. Br Heart J 1981; 46 (5): 522–7.
  10. Sharpe D.N, Coxon R.J. Clinical and haemodynamic effects of low dose captopril in severe chronic heart failure. Br J Clin Phatmacol 1982; 14 (Suppl. 2): 161S–167S.
  11. Nicholls M.G, Espiner E.A, Ikram H et al. Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. J Clin Endocrinol Metab 1981; 52 (6): 1253–6.
  12. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82 (5): 1730–6.
  13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316 (23): 1429–35.
  14. Staessen J, Lijnen P, Fagard R et al. Rise in plasma concentration of aldosterone during long - term angiotensin II suppression. J Endocrinol 1981; 91 (3): 457–65.
  15. Borghi C, Boschi S, Ambrosioni E et al. Evidence of a partial escape of reninangiotensine - aldosterone blocade in patients with acute myocardial infarctiontreated with ACE inhibitors. J Clin Pharmacol 1993; 33 (1): 40–5.
  16. Lee A.F, Mac Fadyen R.J, Struthers A.D. Neurohormonal reactivationin heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1 (4): 401–6.
  17. Мареев В.Ю., Скворцов А.А., Челмакина С.М. и др. Способны ли ингибиторы АПФ эффективно контролировать активность ренин - ангиотензин - альдостероновой системы при длительном лечении хронической сердечной недостаточности? Кардиология. 1999; 39 (2): 27–34.
  18. Urata H, Healy B.H, Stewart R et al. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990; 66 (4): 883–90.
  19. Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monogr Endocrinol, 2nd ed NY.: Springer-Verlag, 1988.
  20. Mac Fadyen R.J, Lee A.F, Morton J.J et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82 (1): 57–61.
  21. Sato A, Saruta T. Aldosterone escape during angiotensin - converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13–21.
  22. Мареев В.Ю., Скворцов А.А. Блокада эффектов альдостерона у больных сердечной недостаточностью: современный взгляд на проблему – эплеренон (ч. II). Сердечная недостаточность. 2011; 12 (4) [66]: 222–7.
  23. Pitt B, Zannand F, Remme W et al. The effect of spirinilactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17.
  24. Delyani J, Myles K, Funder J et al. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens 1998; 11: 94A.
  25. Degasparo M, Joss U, Ramjoue et al. Three new epoxy - spironolactone derivates: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650–6.
  26. Cook C.S, Berry L.M, Kim D.H et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002; 30 (12): 1344–51.
  27. Weinberger M.H, Roniker B, Krause S.L, Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild - to - moderate hypertension. Am J Hypertens 2002; 15 (8): 709–16.
  28. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 1973; 185 (3): 686–95.
  29. Pitt B, Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose – finding study in patients with heart failure. J Am Coll Cardiol 1999; 33: 188A–9A.
  30. Zannad F, Mc Murray J.J.V, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010; 12 (6): 617–22.
  31. Zannad F, Mc Murray J.J.V, Krum H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11–21.
  32. Swedberg K, Zannad F, Mc Murray J.J et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598–603.
  33. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348: 1309–21.
  34. Mottram P.M, Haluska B, Leano R et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110 (5): 558–65.
  35. Mak G.J, Ledwidge M.T, Watson C.J et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54 (18): 1674–82.
  36. Edwards N.C, Ferro C.J, Kirkwood H et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010; 106 (10): 1505–11.
  37. Deswal A, Richardson P, Bozkurt B, Mann D.L. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 2011; 17 (8): 634–42.
  38. Edelmann F.W.R, Schmidt A.G et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA 2013; 309 (8): 781–91.
  39. Desai A.S, Lewis E.F, Li R et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011; 162 (6): 966–72, e910.
  40. Guichard J, Donald Clark I.I, Calhoun D.A et al. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).